VAXCYTE, INC. Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
VAXCYTE, INC. (PCVX) reported Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of $733.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-05
- VAXCYTE, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2026-03-31 was -$664.00K, a 156.66% decline year-over-year.
- VAXCYTE, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2025-03-31 was $1.17M, a 80.67% decline year-over-year.
- VAXCYTE, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2024-03-31 was $6.06M, a 26256.52% increase year-over-year.
- VAXCYTE, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2023-03-31 was $23.00K.
- VAXCYTE, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2025 was $2.44M, a 472.54% increase from fiscal 2024.
- VAXCYTE, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2024 was $426.00K.
- VAXCYTE, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2023 was -$6.69M, a 4980.29% decline from fiscal 2022.
- VAXCYTE, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2022 was $137.00K.
| Period end | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12 month |
|---|---|---|---|---|
| 2026-06-30 | $733.00K 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | -$664.00K 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | $2.44M 10-K · filed 2026-02-24 | |||
| 2025-09-30 | $2.26M 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | $1.97M 10-Q · filed 2026-08-05 | |||
| 2025-03-31 | $1.17M 10-Q · filed 2026-05-06 | |||
| 2024-12-31 | $426.00K 10-K · filed 2026-02-24 | |||
| 2024-09-30 | -$924.00K 10-Q · filed 2025-11-04 | |||
| 2024-06-30 | $4.65M 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | $6.06M 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | -$6.69M 10-K · filed 2026-02-24 | |||
| 2023-09-30 | $996.00K 10-Q · filed 2024-11-05 | |||
| 2023-06-30 | -$55.00K 10-Q · filed 2024-08-06 | |||
| 2023-03-31 | $23.00K 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $137.00K 10-K · filed 2025-02-25 | |||
| 2022-09-30 | -$659.00K 10-Q · filed 2023-11-06 | |||
| 2022-06-30 | -$712.00K 10-Q · filed 2023-08-08 | |||
| 2022-03-31 | -$227.00K 10-Q · filed 2023-05-08 | |||
| 2021-12-31 | -$439.00K 10-K · filed 2024-02-27 | |||
| 2021-09-30 | $363.00K 10-Q · filed 2022-11-07 | |||
| 2021-06-30 | $30.00K 10-Q · filed 2022-08-08 | |||
| 2021-03-31 | -$281.00K 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | $87.00K 10-K · filed 2023-02-27 | |||
| 2019-12-31 | -$341.00K 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |